Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
13 hedge funds and large institutions have $533K invested in Avenue Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
2% more capital invested
Capital invested by funds: $520K → $533K (+$12.2K)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$37.7K |
| 2 |
Renaissance Technologies
New York
|
+$19.7K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$19.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$55K |
| 2 |
VF
Virtu Financial
New York
|
-$38K |
| 3 |
Citigroup
New York
|
-$20.1K |
| 4 |
BCM
Bayesian Capital Management
Brooklyn,
New York
|
-$12.8K |
| 5 |
Morgan Stanley
New York
|
-$3.51K |
ATXI Hedge Fund Activity: Q1 2023 in Review
13 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2023, worth a combined $533K — up 2.4% from $520K a quarter earlier.
Fund positioning in ATXI was balanced in Q1 2023: 5 funds opened new positions, 5 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $37.7K. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $55K sold.
- 13 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $533K of Avenue Therapeutics, Inc. Common Stock stock for Q1 2023, up 2.4% quarter-over-quarter.
- 5 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of 0 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q1 2023 was State Street, an estimated $37.7K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2023 was Qube Research & Technologies (QRT), an estimated $55K sold.
Based on aggregated 13F filings for Q1 2023.